American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Metabolic Disruption as a Clinical Early Warning Signal: a Review of Systems Metabolite Flux Analysis

Waleed Khalid Ahmed*[1], Mohammed Amer Fayyad[2], Jamal A. AL-Jabbar Attawi[3]
[1,2] Chemistry and Biochemistry Department, College of Medicine, University of Fallujah, Iraq
[3] Gilgamesh University, Baghdad, Iraq
*Correspondence: waleed.k.ahmed@uofallujah.edu.iq

Citation: Ahmed, W. K., Fayyad, M. A., Attawi, J. A. A. Metabolic Disruption as a Clinical Early Warning Signal: a Review of Systems Metabolite Flux Analysis. American Journal of Biomedicine and Pharmacy 2026, 3(1), 1-7.

Received: 30th Nov 2025
Revised: 15th Dec 2025
Accepted: 25th Dec 2025
Published: 04th Jan 2026

Abstract: This review aims to consider the use of systemic metabolite flux analysis as a sensitive methodology for diagnosing early metabolic disturbance in clinical practice. In contrast to traditional static biomarker measurements, metabolic flux analysis quantifies real-time metabolite flow through biochemical pathways, providing information about physiological dysfunction. The review investigates such methodological methods as isotopic tracer methods with a special focus on ^{13}C metabolic flux analysis (^{13}C-MFA), and constraint-based modelling. Oncology, metabolic disorders, and neurodegenerative diseases exhibit evidence that flux variations are antecedent to, or significantly ahead of, conventional diagnostic markers in time. Technical barriers are also discussed in the review, and, as future solutions, a translational framework for the clinical application of flux-based diagnostics as a warning system.

Keywords: Metabolic Flux Analysis, Early Warning Signal, Isotopic Tracing, Metabolic Disruption, Clinical Diagnostics, ^{13}C-MFA, Systems Medicine

1. Introduction

Metabolic disruption is one of the first observable signs of pathological conditions, usually occurring before clinical manifestations in years or even decades [1]. Conventional diagnostic methods that rely on fixed biomarker levels do not always detect such impending alterations, as they are not sufficiently sensitive or specific [2]. This review hypothesises that systemic metabolite flux analysis, i.e., the quantitative measurement of metabolite flow through biochemical pathways, has greater potential for early disease detection.

The biochemical principle of this method is that metabolic fluxes (vi) are the net reaction rates via enzymatic pathways that can be expressed as follows: vi = Vmax * ([S]/(Km + [S])) * (Π regulatory factors) [3]. According to Metabolic Control Analysis, flux control coefficients measure the effect of small changes in the major regulatory enzymes on the process, producing disproportionate changes in flux while keeping metabolite levels constant, akin to homeostasis [4].

Recent technological improvements in stable isotope tracing techniques, especially ^{13}C metabolic flux analysis (^{13}C-MFA), and in computational modelling have made it possible to quantitatively determine metabolic fluxes in clinically relevant settings [5]. The purpose of the review is to summarise the existing evidence that substantiates the claim that flux changes serve as an early warning factor, to outline methodological strategies, and to outline strategies to implement the proposed change in clinical practice.

2. Methodological Foundations of Systemic Metabolite Flux Analysis

2.1 Isotopic Tracer Methodologies :

Experimental flux analysis is based on stable isotope tracing. Various labelling patterns give certain metabolic information.

[1, 2 -^{13}C]glucose: After the process of glycolysis, [3 -^{13}C]pyruvate is obtained. The process of pyruvate dehydrogenase (PDH) decarboxylase to [2-^{13}C]acetyl-CoA provides the ability to differentiate between the PDH flux and the pyruvate carboxylase flux [6].

[U-^{13}C]glutamine: It enters the TCA cycle through the transformation to a α-ketoglutarate, and the patterns of labelling are used to differentiate anaplerotic and cataplerotic fluxes [7].

[U-^{13}C]palmitate: β-oxidation results in acetyl-CoA units that have patterned labelling that indicates the source of acetyl-CoA between the mitochondria and the cytosol [8].

2.2 Analytical Platforms for Isotopomer Analysis:

2.2.1 Mass spectrometry approaches measure mass isotopomer distributions (MIDs), where M_measured = Σ_i P_i * B(n, p_i), with P_i representing pathway proportion and B(n, p_i) the binomial distribution [9].

2.2.2 NMR gives ^{13}C-^{13}C scalar coupling patterns, which give direct evidence of bond connectivity, which is essential in the separation of metabolic pathways [10].

2.2.3 Hyperpolarized ^{13}C-NMR makes it possible to measure the flux in the body in real-time by increasing the signal intensity of ^{13}C many times, allowing metabolic fluxes to be monitored at seconds to minutes scales [11].

2.3 Computational Modelling Frameworks:

2.3.1 Constraint-based modelling using stoichiometric matrix (S-v = 0) under thermodynamic and capacity constraints [12].

2.3.2 Elementary Metabolite Unit (EMU) The EMU modelling breaks down metabolites into computationally solvable units and still maintains labelling information [13].

2.3.3 Kinetic models use Michaelis-Menten equations **vi = (Vmax, i* [S])/(Km, i * (1 + [I]/K_i) + [S])**, which are computationally intensive but more detailed predictions [14].

Table 1. Key Enzymatic Parameters in Human Metabolic Flux Analysis.

Enzyme	EC Number	Pathway	Km (mM)	k_cat (s^{-1})	Key Regulators	Clinical Relevance
Hexokinase	2.7.1.1	Glycolysis	0.05	50-100	Inhibited by G6P	Early diabetes detection
Pyruvate Dehydrogenase	1.2.4.1	PDH complex	0.04	10-20	Phosphorylation regulated	Metabolic syndrome
Glutaminase	3.5.1.2	Glutaminolysis	2-5	50-100	Activated by phosphate	Cancer metabolism
Carnitine Palmitoyltransferase I	2.3.1.21	Fatty acid oxidation	0.03	15-25	Inhibited by malonyl-CoA	Cardiac metabolism

3. Clinical Evidence: Flux Alterations as Early Warning Signals

3.1 Oncology: Metabolic Reprogramming Preceding Malignancy:

The formation of cancers is accompanied by metabolic reprogramming, which usually precedes morphological alterations. ^{11}C-MFA research indicates:

3.1.1 When the transformation is in the initial stages, there is **enhanced aerobic glycolysis** (Warburg effect). In a breast ductal carcinoma in situ (DCIS), there is augmented pentose phosphate flux before invasion occurs [15].

3.1.2 Glutamine metabolism rewiring shows increased glutaminolysis in pancreatic intraepithelial neoplasia (PanIN) before carcinoma development [16].

3.1.3 Lipogenic flux activation measured via ^{13}C-acetate incorporation reveals increased de novo lipogenesis in prostate intraepithelial neoplasia [17].

Table 2. Early Flux Alterations in Pre-Malignant States.

Cancer Type	Early Flux Alteration	Tracer Method	Detection Lead Time
Breast	↑ PPP flux, ↑ serine biosynthesis	[1,2-^{13}C]glucose	6-24 months
Colorectal	Altered butyrate metabolism	^{13}C-butyrate	12-36 months
Pancreatic	↑ Glutaminolysis	[U-^{13}C]glutamine	6-18 months

4. Metabolic Syndrome and Type 2 Diabetes

Flux analysis provides sensitive detection of insulin resistance:

4.1 Hepatic glucose production measured via [6,6-$^{2}H_2$]glucose reveals elevated rates in individuals with normal fasting glucose but impaired tolerance [18].

4.2 Skeletal muscle metabolism assessed by [U-^{13}C]glucose infusion shows impaired insulin-stimulated glucose uptake before hyperglycemia [19].

4.3 Adipose tissue lipolysis measured via $^{2}H_5$-glycerol demonstrates elevated basal lipolysis preceding systemic lipid abnormalities [20].

5. Discussion

5.1 Alzheimer's disease shows reduced cerebral metabolic rate of glucose via [^{18}F]FDG-PET and ^{13}C-MRS in presymptomatic individuals [21].

5.2 Parkinson's disease exhibits reduced dopamine synthesis capacity via ^{18}F-DOPA PET kinetics before motor symptoms [22].



Figure 1. Comparative Systemic Flux Maps in Health vs. Early Disease States

(Diagram showing whole-body flux distributions for glucose, fatty acids, and amino acids in healthy individuals versus those with early metabolic syndrome and pre-cancerous states).

6. Integration with Multi-Omics and Clinical Data

6.1 Systems Biology Approaches :

6.1.1 Multi-omics integration combines flux data with transcriptomic, proteomic, and metabolomic information via methods like E-Flux and GECKO models [23].

6.1.2 Personalised metabolic models Personalised metabolic models build patient-specific metabolic networks with transcriptomic and proteomic restrictions based on individual genomic information [24].

7. Clinical Data Integration

7.1 Electronic health record integration uses the standardised data models (OHDSI OMOP CDM) to incorporate data on fluxes [25].

7.2 Machine learning strategies recognise patterns of fluctuation of clinical outcomes, which facilitates predictive diagnostics [26].

7.3 Digital health technologies can monitor flux-correlated parameters at any moment, such as wearable sensors and mobile applications [27].

8. Challenges and Limitations

8.1 Technical and Methodological Challenges :

8.1.1 Effects of isotopic dilution in complex biological systems are problematic in quantifying flux [28].

8.1.2 Compartmentation issues are due to varying patterns of flux in the subcellular compartments [29].

8.1.3 Uncertainty of Enzyme kinetic parameters when kcat uncertainties are typically large (more than an order of magnitude) has implications on flux predictions [30].

8.2 Clinical Implementation Challenges :

8.2.1 The considerations of study design involve optimisation of tracer selection, dosing and sampling protocols [31].

8.2.2 Regulatory routes should be developed regarding a flux-based diagnostics permission [32].

8.2.3 Economic factors should be shown to be cost-effective as compared to available methods [33].

9. Future Directions and Clinical Translation

9.1 Technological Advancements :

9.1.1 The single-cell flux with microfluidic devices combined with sensitive MS allows the evaluation of the cellular heterogeneity [34].

9.1.2 In vivo flux imaging. Advanced hyperpolarised NMR techniques can be used to monitor organs in real time [35].

9.1.3 Portable MS systems enable point-of-care flux sensorimeters to be used in clinical situations [36].

10. Clinical Implementation Framework

Phase 1: Validation and Standardisation (1-3 years)

- Multicenter validation studies.
- Clinical practice guideline development.
- Reference range establishment.

Phase 2: Integration into Clinical Pathways (3-7 years)

- Inclusion into screening programs.
- Clinical decision support tools development.
- Healthcare provider training: This is performed by both the hospital and the government.

Phase 3: Routine Clinical Implementation (7+ years)

- Widespread diagnostic availability.
- Personalised medicine integration.
- Continuous refinement via real-world evidence.

11. Review Priorities

11.1 Basic review requirements are full human enzyme kinetic parameters and metabolon structure-function relationships [37].

11.2 Translational review must concern itself with the biomarker validation, assay development, and clinical utility studies [38].



Figure 2. Translational Pathway for Clinical Implementation of Flux Analysis.

12. Conclusion

Systemic metabolite flux analysis is a new paradigm for early disease diagnosis, providing biochemical information previously unavailable with traditional methods. The quantification of reaction velocity based on metabolic networks provides sensitive indicators of physiological status that can often precede changes in traditional biomarkers.

The prospect of flux-based early warning signals is consistently supported by clinical evidence across various disease domains. Although aggressive implementation issues are also crucial, they can be eliminated through the adoption of technological advancements and collaboration.

In the future, longitudinal flux studies should be prioritised in populations at the risk, simplified clinical assays should be developed and combined with artificial intelligence techniques to learn about the data. The convergence of technologies in the field of accurate measurements, advanced computing solutions, and systems bioengineering offers the first opportunities to transform the technology of reactive treatment of diseases into active care of health.

With the continuously rising level of analytical skill and the knowledge of controlling the metabolic processes, flux analysis will be an inseparable element of clinical practice, which will be in essence capable of diagnosing the disease at the earliest and most treatable stages.

References

[1] P. Horn and F. Tacke, "Metabolic reprogramming in liver fibrosis," *Cell Metabolism*, vol. 36, no. 7, pp. 1439–1455, 2024.

[2] S. Kersten, "The impact of fasting on adipose tissue metabolism," *Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids*, vol. 1868, no. 3, Art. no. 159262, 2023.

[3] A. Cornish-Bowden, *Fundamentals of Enzyme Kinetics*, 4th ed. Hoboken, NJ, USA: Wiley-Blackwell, 2013.

[4] H. Kacser and J. A. Burns, "The control of flux," *Symposia of the Society for Experimental Biology*, vol. 27, pp. 65–104, 1973.

[5] M. R. Antoniewicz, "A guide to ^{13}C metabolic flux analysis for the cancer biologist," *Experimental & Molecular Medicine*, vol. 50, no. 4, pp. 1–13, 2018.

[6] J. M. Buescher *et al*., "A roadmap for interpreting ^{13}C metabolite labelling patterns from cells," *Current Opinion in Biotechnology*, vol. 34, pp. 189–201, 2015.

[7] R. J. DeBerardinis *et al*., "Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis," *Proceedings of the National Academy of Sciences*, vol. 104, no. 49, pp. 19345–19350, 2007.

[8] T. R. Koves *et al*., "Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance," *Cell Metabolism*, vol. 7, no. 1, pp. 45–56, 2008.

[9] M. R. Antoniewicz *et al*., "Elementary metabolite units (EMU): a novel framework for modelling isotopic distributions," *Metabolic Engineering*, vol. 9, no. 1, pp. 68–86, 2007.

[10] C. R. Malloy *et al*., "Analysis of intermediary metabolism using stable isotopes," *Journal of Biological Chemistry*, vol. 265, no. 25, pp. 15496–15500, 1990.

[11] J. Kurhanewicz *et al*., "Hyperpolarised ^{13}C MRI: path to clinical translation in oncology," *Neoplasia*, vol. 21, no. 1, pp. 1–16, 2019.

[12] J. D. Orth, I. Thiele, and B. Ø. Palsson, "What is flux balance analysis?" *Nature Biotechnology*, vol. 28, no. 3, pp. 245–248, 2010.

[13] J. D. Young *et al*., "An elementary metabolite unit (EMU)-based model of intermediary metabolism and its application to the analysis of ^{13}C labelling data," *Metabolic Engineering*, vol. 10, no. 6, pp. 321–332, 2008.

[14] K. Smallbone *et al*., "A model of yeast glycolysis based on a consistent kinetic characterisation of all its enzymes," *FEBS Letters*, vol. 584, no. 11, pp. 2367–2371, 2010.

[15] G. J. Yoshida, "Metabolic reprogramming: the emerging concept and associated therapeutic strategies," *Journal of Experimental & Clinical Cancer Research*, vol. 34, Art. no. 111, 2015.

[16] J. Son *et al*., "Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway," *Nature*, vol. 496, no. 7443, pp. 101–105, 2013.

[17] N. Zaidi *et al*., "ATP citrate lyase: a key metabolic enzyme as a novel therapeutic target in cancer," *Cancer Research*, vol. 72, no. 14, pp. 3709–3714, 2012.

[18] G. Boden *et al*., "Increased hepatic glucose production in obese subjects with impaired glucose tolerance," *Journal of Clinical Investigation*, vol. 125, no. 5, pp. 1927–1932, 2015.

[19] M. A. Abdul-Ghani *et al*., "What if we do not go to bed? The impact of acute sleep restriction on insulin sensitivity in healthy subjects," *Diabetes*, vol. 55, no. 5, pp. 1430–1435, 2006.

[20] T. S. Nielsen *et al*., "Fasting, but not exercise, increases adipose triglyceride lipase (ATGL) protein and reduces G0/G1 switch gene 2 (G0S2) protein and mRNA content in human adipose tissue," *Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 2, pp. E328–E335, 2014.

[21] L. Mosconi *et al*., "Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease," *Psychiatry Research: Neuroimaging*, vol. 164, no. 3, pp. 253–266, 2008.

[22] Y. Kumakura *et al*., "Elevated [^{18}F]FDOPA uptake in the striatum of patients with early Parkinson's disease: a PET study," *Journal of Nuclear Medicine*, vol. 48, no. 6, pp. 914–920, 2007.

[23] C. Colijn *et al*., "Interpreting expression data with metabolic flux models: predicting *Mycobacterium tuberculosis* mycolic acid production," *PLoS Computational Biology*, vol. 5, no. 8, Art. no. e1000489, 2009.

[24] R. Agren *et al*., "Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT," *PLoS Computational Biology*, vol. 8, no. 5, Art. no. e1002518, 2012.

[25] G. Hripcsak *et al*., "Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers," *Studies in Health Technology and Informatics*, vol. 216, pp. 574–578, 2015.

[26] T. Ching *et al*., "Opportunities and obstacles for deep learning in biology and medicine," *Journal of the Royal Society Interface*, vol. 15, no. 141, Art. no. 20170387, 2018.

[27] J. Dunn *et al*., "Wearable sensors enable personalised predictions of clinical laboratory measurements," *Nature Medicine*, vol. 27, no. 6, pp. 1105–1112, 2021.

[28] M. R. Antoniewicz, "Methods and advances in metabolic flux analysis: a mini-review," *Journal of Industrial Microbiology & Biotechnology*, vol. 42, no. 3, pp. 317–325, 2015.

[29] W. W. Chen *et al*., "Input-output behaviour of ErbB signalling pathways as revealed by a mass action model trained against dynamic data," *Molecular Systems Biology*, vol. 5, Art. no. 239, 2009.

[30] N. J. Stanford *et al*., "Systematic construction of kinetic models from genome-scale metabolic networks," *PLoS One*, vol. 8, no. 11, Art. no. e79195, 2013.

[31] D. S. Wishart, "Emerging applications of metabolomics in drug discovery and precision medicine," *Nature Reviews Drug Discovery*, vol. 15, no. 7, pp. 473–484, 2016.

[32] U.S. Food and Drug Administration, *Digital Health Innovation Action Plan*, 2020.

[33] G. D. Sanders *et al*., "Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine," *JAMA*, vol. 316, no. 10, pp. 1093–1103, 2016.

[34] R. Zenobi, "Single-cell metabolomics: analytical and biological perspectives," *Science*, vol. 342, no. 6163, Art. no. 1243259, 2013.

[35] S. J. Nelson *et al*., "Metabolic imaging of patients with prostate cancer using hyperpolarised [1-^{13}C]pyruvate," *Science Translational Medicine*, vol. 5, no. 198, Art. no. 198ra108, 2013.

[36] Z. Ouyang and R. G. Cooks, "Miniature mass spectrometers," *Annual Review of Analytical Chemistry*, vol. 2, pp. 187–214, 2009.

[37] B. D. Bennett *et al*., "Absolute metabolite concentrations and implied enzyme active site occupancy in *Escherichia coli*," *Nature Chemical Biology*, vol. 5, no. 8, pp. 593–599, 2009.

[38] R. Kaddurah-Daouk *et al*., "Metabolomics: a global biochemical approach to drug response and disease," *Annual Review of Pharmacology and Toxicology*, vol. 48, pp. 653–683, 2008.